10 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 15 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 10, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Neurotoxicity Syndromes: new trials by email Literature Review of Neurotoxicity Syndromes trials Research Report on Neurotoxicity Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia IMM02-KORA - Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced | Phase 1 | Not yet recruiting | Immunis, Inc. | 15 | 2026-11-30 | 2026-10-30 |
| Atamparib in Patients With Advanced Solid Tumors atamparib escalation levels, atamparib RP2D - NSCLC Adenocarcinoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Nerviano Medical Sciences (Shanghai) Ltd. | 178 | 2026-03-18 | 2026-07-29 |
| Study of the Drug B11-FC (Botulism Treatment) B11-FC, Botulinum neurotoxin type A, Placebo - Botulism | Phase 1 / Phase 2 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 40 | 2024-08-01 | 2024-08-30 |
| Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA Amifampridine - Botulism, Iatrogenic Botulism | Phase 1 | Completed | Wake Forest University Health Sciences | 21 | 2023-09-15 | 2025-02-03 |
| Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects G03-52-01, Placebo - Healthy | Phase 1 | Completed | Alachua Government Services, Inc. | 40 | 2020-06-01 | 2024-10-04 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma iC9-CAR19 T cells, Bendamustine, Fludarabine - Lymphoma, Lymphoma, B-Cell | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2019-03-12 | 2026-07-31 |
| A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults NTM-1633, Placebo - Botulism | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2018-09-25 | 2022-06-22 |
| Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632 NTM-1632, Placebo - Botulism | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2016-08-01 | 2018-10-29 |
| Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder oxytocin, placebo - Alcoholism, Alcohol Related Disorders | Phase 1 | Completed | Johns Hopkins University | 27 | 2015-03-01 | 2017-12-04 |
| Phase 1 PK Study of XOMA 3AB XOMA 3AB, Placebo - Botulism | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2011-05-01 | 2014-12-05 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 23 | 2009-02-01 | 2014-12-31 |
| Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma glucarpidase, leucovorin calcium, methotrexate - Chemotherapeutic Agent Toxicity, Lymphoma | Phase 1 / Phase 2 | Completed | University College, London | 4 | 2008-07-01 | 2014-01-27 |
| Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases lithium carbonate, cognitive assessment, quality-of-life assessment - Brain and Central Nervous System Tumors, Cognitive/Functional Effects | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 9 | 2006-02-01 | 2012-02-28 |
| Movement Disorders Caused by Antipsychotic Drugs in Older Patients Quetiapine, Risperidone, Olanzapine - Dyskinesia, Drug-Induced | Phase 1 | Completed | University of California, San Diego | 250 | 1999-01-01 | 2013-06-06 |
| A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia Vincristine - Acute Lymphocytic Leukemia, Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 90 | 1998-01-01 | 2008-03-04 |
Botulism (6) · Dyskinesia, Drug-Induced (2) · Lymphoma (2) · Alcohol Withdrawal Delirium (1) · Alcohol-Related Disorders (1) · Alcoholism (1) · Brain Neoplasms (1) · Brenner Tumor (1) · Central Nervous System Neoplasms (1) · Cytokine Release Syndrome (1) · Dyskinesias (1) · Fallopian Tube Neoplasms (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1)
Chemically-Induced Disorders (15) · Nervous System Diseases (15) · Poisoning (15) · Bacterial Infections (6) · Bacterial Infections and Mycoses (6) · Clostridium Infections (6) · Foodborne Diseases (6) · Gram-Positive Bacterial Infections (6) · Infections (6) · Neuromuscular Diseases (6) · Neuromuscular Junction Diseases (6) · Neoplasms (5) · Central Nervous System Diseases (4) · Neoplasms by Histologic Type (4)
Radiotherapy (2) · AP 1903 reagent (1) · Amifampridine (1) · Bendamustine Hydrochloride (1) · Benzyl Alcohols (1) · Botulinum Toxins, Type A (1) · Cisplatin (1) · Cyclophosphamide (1) · Leucovorin (1) · Lithium (1) · Lithium Carbonate (1) · Mental Status and Dementia Tests (1) · Methotrexate (1) · Olanzapine (1) · Oxytocin (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Alachua Government Services, Inc. (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Gynecologic Oncology Group (1) · Immunis, Inc. (1) · Johns Hopkins University (1) · National Cancer Institute (NCI) (1) · Nerviano Medical Sciences (Shanghai) Ltd. (1) · UNC Lineberger Comprehensive Cancer Center (1) · University College, London (1) · University of California, San Diego (1) · Vanderbilt-Ingram Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (11) · China (1) · United Kingdom (1)
Bo Lu, MD, PhD (1) · Caicun Zhou, Dr. (1) · Cassandra Key, MD (1) · Dilip V. Jeste, MD (1) · Don Dizon (1) · Elise Weerts, Ph.D. (1) · James B Caress, MD (1) · Mani Nistor (1) · Natalie Grover, MD (1) · Roderick Johnson, MD (1)
K12CA120780 (1), R01MH059101 (1), U10CA027469 (1)